Skip to content
    ArrowMark Partners logo

    ArrowMark Partners

    Denver, Colorado, United StatesFounded 2007
    www.arrowmarkpartners.comLinkedIn
    Biotech & Life SciencesHealthcare

    ArrowMark Partners is a privately held, employee-owned investment management firm founded in 2007 and headquartered in Denver, Colorado. The firm manages over $18 billion in assets across credit (private credit, alternative credit, CLOs/leveraged loans), real estate (CRE structured finance, bridge lending), and equity (long-only, life science, hedged equity) strategies, with a life science arm focused on early-stage biotech investing and company creation.

    39% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $110.3M (across 40 rounds with reported amounts).

    Find people at ArrowMark Partners on Goldilocks AI

    Portfolio

    34

    Fund Size

    $1.1B

    Top Stage

    Series B

    Last 12 Mo

    1

    Team

    BS

    Brian Schaub

    Partner, Portfolio Manager

    CM

    Chad Meade

    Partner, Portfolio Manager

    DC

    David Corkins

    Partner, Portfolio Manager

    KA

    Kaelyn Abrell

    Partner, Portfolio Manager

    KR

    Karen Reidy

    Partner, Portfolio Manager

    KR

    Kirk Reid

    Partner, Chief Operations & Technology Officer

    RB

    Rob Brown

    Partner, Portfolio Manager

    SB

    Sanjai Bhonsle

    Partner, Portfolio Manager

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    41 investments
    CompanyRoundAmountDate
    Skyryse logoSkyryseSeries C$300MFeb 2026
    Arbor Biotechnologies logoArbor BiotechnologiesSeries C$73.9MMar 2025
    FFreenomeGrowth$254MFeb 2024
    SSmartLabsSeries C$48MJan 2024
    Beta Bionics logoBeta BionicsSeries C$57MFeb 2022
    BBeta Bionics, Inc.Series C$57MFeb 2022
    Simcha Therapeutics logoSimcha TherapeuticsSeries B$40MJan 2022
    Arbor Biotechnologies logoArbor BiotechnologiesSeries B$215MNov 2021
    FFylloSeries C$40MNov 2021
    Skyryse logoSkyryseSeries B$205MOct 2021
    Formation Bio logoFormation BioSeries C$156MSep 2021
    BBinx HealthSeries E$104MMay 2021
    AbSci logoAbSciGrowth$125MMar 2021
    Amunix logoAmunixSeries B$117MMar 2021
    AAmunix PharmaceuticalsSeries B$117MMar 2021
    AAmunix PharmaceuticalsSeries B$117MJan 2021
    MaxCyte logoMaxCyteUnknown—Jan 2021
    Adagio Medical logoAdagio MedicalSeries E$42.5MNov 2020
    Xometry logoXometryGrowth$75MSep 2020
    44DMTSeries C$75MJun 2020
    SSonendoGrowth$85MJan 2020
    Beta Bionics logoBeta BionicsSeries B$63MJan 2019
    4D Molecular Therapeutics logo4D Molecular TherapeuticsSeries B$90MSep 2018
    44DMTSeries B$90MSep 2018
    Orchard Therapeutics logoOrchard TherapeuticsSeries C$150MAug 2018
    Page 1 of 2

    Top Co-Investors

    Perceptive Advisors11 shared
    Casdin Capital9 shared
    RA Capital Management8 shared
    Polaris Partners8 shared
    Redmile Group7 shared
    Viking Global Investors6 shared
    Venrock5 shared
    T. Rowe Price5 shared
    RTW Investments, LP4 shared
    Soleus Capital4 shared
    Longitude Capital4 shared
    Franklin Templeton4 shared
    Omega Funds4 shared
    Ridgeback Capital4 shared
    Cormorant Asset Management4 shared
    SR One4 shared
    Pura Vida Investments3 shared
    Eventide Asset Management3 shared
    LifeSci Venture Partners3 shared
    Fidelity Investments3 shared

    Last updated: 8 September 2026